Literature DB >> 23090376

Selective inhibition of cyclooxygenase-2: risks and benefits.

Reila Tainá Mendes1, Cassiano Pereira Stanczyk, Regina Sordi, Michel Fleith Otuki, Fábio André dos Santos, Daniel Fernandes.   

Abstract

The cyclooxygenase (COX) inhibitors are the most common drugs used worldwide. COX corresponds to an evolutionarily conserved class of enzymes and has two main isoforms: COX-1, which is largely associated with physiological functions, and COX-2, which is largely associated with pathological functions. Their subproducts have an important role in inflammation and pain perception. The COX-2 selective inhibition was designed to minimize gastrointestinal complications of non-selective inhibition. However, this exclusive COX-2 inhibition was associated with serious cardiovascular events, for causing an imbalance between prostacyclin and thromboxane production. The objective of this study is to discuss the mechanisms underlying the cardiovascular effects, pointing out the advantages and disadvantages of the selective or nonselective COX inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23090376

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  8 in total

Review 1.  The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis.

Authors:  Sang Jun Han; Bert W O'Malley
Journal:  Hum Reprod Update       Date:  2014-03-14       Impact factor: 15.610

2.  Revisiting the role of COX-2 inhibitor for non-small cell lung cancer.

Authors:  Hiroshi Yokouchi; Kenya Kanazawa
Journal:  Transl Lung Cancer Res       Date:  2015-10

3.  Anti-inflammatory Activity of Magnesium Isoglycyrrhizinate Through Inhibition of Phospholipase A2/Arachidonic Acid Pathway.

Authors:  Chunfeng Xie; Xiaoting Li; Jieshu Wu; Zhaofeng Liang; Feifei Deng; Wei Xie; Mingming Zhu; Jianyun Zhu; Weiwei Zhu; Shanshan Geng; Caiyun Zhong
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

4.  Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.

Authors:  Hiroshi Yokouchi; Kenya Kanazawa; Takashi Ishida; Satoshi Oizumi; Naofumi Shinagawa; Noriaki Sukoh; Masao Harada; Shigeaki Ogura; Mitsuru Munakata; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
Journal:  Mol Clin Oncol       Date:  2014-06-19

5.  Genome-Wide Analysis Indicates a Complete Prostaglandin Pathway from Synthesis to Inactivation in Pacific White Shrimp, Litopenaeus vannamei.

Authors:  Hao Yang; Xiaoli Chen; Zhi Li; Xugan Wu; Mingyu Zhou; Xin Zhang; Yujie Liu; Yuying Sun; Chunhua Zhu; Qiuhui Guo; Ting Chen; Jiquan Zhang
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

6.  Anti-Inflammatory, Analgesic and Antioxidant Potential of New (2S,3S)-2-(4-isopropylbenzyl)-2-methyl-4-nitro-3-phenylbutanals and Their Corresponding Carboxylic Acids through In Vitro, In Silico and In Vivo Studies.

Authors:  Fawad Mahmood; Jamshaid Ali Khan; Mater H Mahnashi; Muhammad Saeed Jan; Muhammad Aamir Javed; Umer Rashid; Abdul Sadiq; Syed Shams Ul Hassan; Simona Bungau
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

7.  The anti-inflammatory effects of Yunnan Baiyao are involved in regulation of the phospholipase A2/arachidonic acid metabolites pathways in acute inflammation rat model.

Authors:  Xiaobin Ren; Mingzhu Zhang; Lingxiang Chen; Wanli Zhang; Yu Huang; Huazhen Luo; Ling Li; Hongbing He
Journal:  Mol Med Rep       Date:  2017-07-27       Impact factor: 2.952

Review 8.  Different Chemical Structures and Physiological/Pathological Roles of Cyclooxygenases.

Authors:  Yalcin Faki; Ayse Er
Journal:  Rambam Maimonides Med J       Date:  2021-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.